-
Je něco špatně v tomto záznamu ?
Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years
R Zivadinov, N Bergsland, O Dolezal, S Hussein, Z Seidl, MG Dwyer, M Vaneckova, J Krasensky, JA Potts, T Kalincik, E Havrdova, D Horakova
Jazyk angličtina Země Spojené státy americké
Grantová podpora
NT13237
MZ0
CEP - Centrální evidence projektů
PubMed
23578679
DOI
10.3174/ajnr.a3503
Knihovny.cz E-zdroje
- MeSH
- adjuvancia imunologická terapeutické užití MeSH
- atrofie patofyziologie patologie MeSH
- azathioprin aplikace a dávkování MeSH
- časná diagnóza MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- interferon beta 1a MeSH
- interferon beta aplikace a dávkování terapeutické užití MeSH
- kombinovaná farmakoterapie MeSH
- lidé MeSH
- longitudinální studie MeSH
- magnetická rezonanční tomografie MeSH
- mladý dospělý MeSH
- mozková kůra * patofyziologie patologie MeSH
- posuzování pracovní neschopnosti * MeSH
- progrese nemoci MeSH
- prospektivní studie MeSH
- relabující-remitující roztroušená skleróza * farmakoterapie patofyziologie patologie MeSH
- steroidy aplikace a dávkování MeSH
- thalamus * patofyziologie patologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
BACKGROUND AND PURPOSE: Pathologic changes in GM have an important role in MS. We investigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P < .001), thalamus (P = .006), and total SDGM (P = .0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18035699
- 003
- CZ-PrNML
- 005
- 20190104103941.0
- 007
- ta
- 008
- 181023s2013 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3174/ajnr.A3503 $2 doi
- 035 __
- $a (PubMed)23578679
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Zivadinov R $u Zivadinov, R. Buffalo Neuroimaging Analysis Center.
- 245 10
- $a Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years / $c R Zivadinov, N Bergsland, O Dolezal, S Hussein, Z Seidl, MG Dwyer, M Vaneckova, J Krasensky, JA Potts, T Kalincik, E Havrdova, D Horakova
- 520 9_
- $a BACKGROUND AND PURPOSE: Pathologic changes in GM have an important role in MS. We investigated the association between SDGM and cortical volume changes and disability progression in early RRMS. MATERIALS AND METHODS: One hundred eighty patients with RRMS had clinical assessment during 5 years and were divided into those with or without SDP at 5 years by the usual definition in treatment trials. The number of available MR imaging scans at various time points was the following: at baseline, 178; and at 6 months, 172; at 12 months, 175; at 24 months, 155; at 36 months, 160; at 48 months, 158; and at 60 months, 162, respectively. Longitudinal changes in cortical, GM, and WM volume were calculated by using the direct method. RESULTS: At 5 years, 90 patients with RRMS experienced SDP and 90 had stable disease. At baseline, patients with SDP had longer disease duration, greater T2-lesion volume, and smaller whole-brain, WM, cortical, and SDGM volume (P < .01). At 5 years, patients with SDP had significantly greater percentage decreases from baseline compared with those without SDP in the volume of the whole brain (P < .0001), cortex (P = .001), GM (P = .003), and thalamus (P = .01). In patients who developed SDP at 5 years and those who did not, mixed-effect models, adjusted for age, disease duration, and change of the treatment status, showed significant interactions between SDP status at 5 years and changes with time in whole-brain, cortical, lateral ventricle (all P < .001), thalamus (P = .006), and total SDGM (P = .0095) volume. CONCLUSIONS: SDP is associated with progression of cortical, central, and thalamic atrophy in early RRMS during 5 years.
- 590 __
- $a bohemika - dle Pubmed
- 650 02
- $a adjuvancia imunologická $x terapeutické užití $7 D000276
- 650 02
- $a dospělí $7 D000328
- 650 02
- $a atrofie $x patofyziologie $x patologie $7 D001284
- 650 02
- $a azathioprin $x aplikace a dávkování $7 D001379
- 650 12
- $a mozková kůra $x patofyziologie $x patologie $7 D002540
- 650 12
- $a posuzování pracovní neschopnosti $7 D004185
- 650 02
- $a progrese nemoci $7 D018450
- 650 02
- $a dvojitá slepá metoda $7 D004311
- 650 02
- $a kombinovaná farmakoterapie $7 D004359
- 650 02
- $a časná diagnóza $7 D042241
- 650 02
- $a ženské pohlaví $7 D005260
- 650 02
- $a lidé $7 D006801
- 650 02
- $a interferon beta 1a $7 D000068556
- 650 02
- $a interferon beta $x aplikace a dávkování $x terapeutické užití $7 D016899
- 650 02
- $a longitudinální studie $7 D008137
- 650 02
- $a magnetická rezonanční tomografie $7 D008279
- 650 02
- $a mužské pohlaví $7 D008297
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $x patofyziologie $x patologie $7 D020529
- 650 02
- $a prospektivní studie $7 D011446
- 650 02
- $a steroidy $x aplikace a dávkování $7 D013256
- 650 12
- $a thalamus $x patofyziologie $x patologie $7 D013788
- 650 02
- $a mladý dospělý $7 D055815
- 700 1_
- $a Bergsland N
- 700 1_
- $a Doležal, Ondřej, $d 1979- $7 xx0075512
- 700 1_
- $a Hussein S
- 700 1_
- $a Seidl, Zdeněk, $d 1950- $7 mzk2004258727
- 700 1_
- $a Dwyer MG
- 700 1_
- $a Vaněčková, Manuela, $d 1973- $7 mzk2007377403
- 700 1_
- $a Krásenský, Jan $7 xx0096156
- 700 1_
- $a Potts JA
- 700 1_
- $a Kalincik T
- 700 1_
- $a Kubala Havrdová, Eva, $d 1955- $7 nlk19990073204
- 700 1_
- $a Horáková, Dana $7 xx0076527
- 773 0_
- $t American journal of neuroradiology $g Roč. 34, č. 10 (2013), s. 1931-1939 $p AJNR Am J Neuroradiol $x 0195-6108 ((tištěná verze)) $w MED00009116
- 773 0_
- $p AJNR Am J Neuroradiol $g 34(10):1931-9, 2013 Oct
- 910 __
- $a ABA008 $y 4 $z 0
- 990 __
- $a 20181023143253 $b ABA008
- 991 __
- $a 20190104104136 $b ABA008
- 999 __
- $a ok $b bmc $g 1345202 $s 1032711
- BAS __
- $a 3
- BMC __
- $a 2013 $b 34 $c 10 $d 1931-1939 $x MED00009116 $i 0195-6108 ((tištěná verze)) $m American journal of neuroradiology
- GRA __
- $a NT13237 $p MZ0
- LZP __
- $a NLK 2018/lp